Melanin production inhibitor

Citronellol, phenethyl alcohol, and nerol are used to suppress COX-2 and IL-1α, addressing the challenges of melanin production inhibitors by providing a safe and effective skin whitening solution through their melanin production inhibition properties.

WO2024237112A1PCT designated stage expired Publication Date: 2024-11-21SHISEIDO CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/016822
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-05-01
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current melanin production inhibitors face challenges due to the use of difficult-to-obtain or unfamiliar raw materials, making it hard to ensure safety, usability, and appropriate dosage, while effectively suppressing melanin production factors like COX-2 and IL-1α.

Method used

The use of citronellol, phenethyl alcohol, and nerol as active ingredients to suppress COX-2 and IL-1α gene expression, thereby inhibiting melanin production, which are easily available and have accumulated human experience, allowing for safe and effective skin whitening.

Benefits of technology

Citronellol, phenethyl alcohol, and nerol effectively decrease COX-2 and IL-1α expression, leading to suppressed melanin production and whitening effects, confirmed through gene expression and protein production measurements, suitable for cosmetic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
  • Figure JPOXMLDOC01-APPB-T000002
    Figure JPOXMLDOC01-APPB-T000002
  • Figure JPOXMLDOC01-APPB-T000003
    Figure JPOXMLDOC01-APPB-T000003
Patent Text Reader

Abstract

Provided is a melanin production inhibitor. The provided melanin production inhibitor contains, as an active ingredient, one or more selected from one or more selected from the group consisting of citronellol, phenethyl alcohol, and nerol.
Need to check novelty before this filing date? Find Prior Art

Description

Melanin production inhibitor

[0001] The present invention relates to a melanin production inhibitor. In particular, the present invention relates to a melanin production inhibitor containing one or more selected from citronellol, phenethyl alcohol, and nerol as an active ingredient, and a composition containing the same.

[0002] There is a widespread demand for the suppression of melanin production. It is well known that ultraviolet rays, oxidation, stress, etc. are major factors in melanin production. For example, it is well known that these factors increase the production of COX-2 and IL-1α, promoting melanin production. COX-2 produces PGE-2 in epidermal cells, and IL-1α increases tyrosinase activity through increased production of EDN-1 and SCF, leading to excessive melanin production.

[0003] One approach that could be considered is to inhibit melanin production and aim for skin whitening by inhibiting these factors. Currently, there are various melanin production inhibitors and skin whitening agents that utilize such an approach, but if raw materials that are difficult to obtain or raw materials that are not accustomed to being used on humans are used, development becomes difficult from the standpoints of availability, safety, usability, and appropriate dosage adjustment. Therefore, it is also necessary to use raw materials that are easily available and have accumulated experience in human use.

[0004] Japanese Patent Application Laid-Open No. 2005-89416

[0005] An object of the present invention is to obtain an agent capable of inhibiting melanin production.

[0006] The present inventors have discovered that citronellol, phenethyl alcohol, and nerol inhibit COX-2 and IL-1α, which are involved in melanin production, and have arrived at the present invention.

[0007] The present invention therefore relates to the following: [1] A melanin production inhibitor containing citronellol or phenethyl alcohol as an active ingredient. [2] An IL-1α gene expression inhibitor containing citronellol or phenethyl alcohol as an active ingredient. [3] A COX2 gene expression inhibitor containing citronellol or phenethyl alcohol as an active ingredient. [4] A cosmetic method for inhibiting melanin production in a subject, comprising applying citronellol or phenethyl alcohol to the subject. [5] A melanin production inhibitor containing nerol as an active ingredient. [6] An IL-1α gene expression inhibitor containing nerol as an active ingredient. [7] A COX2 gene expression inhibitor containing nerol as an active ingredient. [8] A cosmetic method for inhibiting melanin production in a subject, comprising applying nerol to the subject.

[0008] By applying citronellol, phenethyl alcohol, or nerol, it becomes possible to suppress COX-2 and IL-1α, and thus melanin production can be inhibited and whitening effects can be expected.

[0009] The present invention provides a melanin production inhibitor and a skin whitening agent containing, as an active ingredient, one or more selected from citronellol, phenethyl alcohol, and nerol.

[0010] Citronellol (CAS number: 106-22-9) is contained in essential oils such as geranium oil and citronella oil, and is an aromatic component that has a rose-like scent.

[0011] Phenethyl alcohol (CAS number: 60-12-8) is found in roses and alcohol, and has a rose-like fragrance and is used as a fragrance. It is also used as a preservative due to its antibacterial properties.

[0012] Nerol (CAS number: 106-25-2) is an aroma component that has a rose-like aroma and is contained in neroli oil, rose oil, etc. Nerol has been reported to have a tyrosinase activity inhibitory effect (Patent Document 1).

[0013] Citronellol, phenethyl alcohol, and nerol are fragrance components used in cosmetics, are readily available, and are easy to develop from the standpoints of safety, usability, and appropriate dosage adjustment. They are also easy-to-use raw materials with a wealth of human experience.

[0014] Inhibition of melanin production and skin whitening can be confirmed by measuring the reduction in gene expression or protein production of COX-2, IL-1α, or the like in biological samples such as keratinocytes and skin fibroblasts. Measurement of gene expression can be performed by techniques known in the art, such as quantitative PCR or Northern blotting. For example, a probe for mRNA of COX2 and / or IL-1α, etc., may be used. Protein levels can be measured by techniques known in the art, such as Western blotting, immunostaining, and ICM. However, in addition to the above-mentioned methods, inhibition of melanin production and / or skin whitening can also be confirmed by any method, such as visual inspection, light reflectance, image analysis, or measurement of specific proteins such as markers such as tyrosinase, melanin, and PGE-2.

[0015] As mentioned above, COX2 (Prostaglandin-Endoperoxide Synthase 2) is a gene encoding the PGE2-producing enzyme involved in melanin production. IL-1α (Interleukin 1 Alpha) increases tyrosinase activity, thereby causing excessive melanin production.

[0016] As described above, gene expression can be measured by techniques known in the art, such as quantitative PCR, Northern blotting, etc. In one embodiment, suppression of gene expression means a decrease that is statistically significant, for example, at a significance level of 5% (e.g., Student's t-test, Dunnett's test), and / or a decrease of, for example, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100%.

[0017] The biological sample may be a sample in which the melanin production inhibitory effect and / or whitening effect can be measured, or a cell culture in which the gene expression level or protein production level of, for example, COX2 and / or IL-1α can be measured. For example, keratinocytes are preferably used. Alternatively, a skin sample or a three-dimensionally constructed cultured skin model may be used. The cells may be derived from any animal, but from the perspective of developing cosmetics and pharmaceuticals, cells derived from humans are preferred.

[0018] The present invention also provides a method for inhibiting melanin production and / or whitening the skin in a subject, comprising applying one or more selected from citronellol, phenethyl alcohol, and nerol, or the agent of the present invention or a composition containing same.

[0019] Examples of subjects to which the method of the present invention can be applied include subjects who have spots, dullness, pigmentation, etc. and who need or desire skin whitening or suppression of melanin production, and subjects with increased gene expression levels or protein production levels of COX2 and / or IL-1α, etc.

[0020] A preferred embodiment is a cosmetic method for inhibiting melanin production and / or whitening the skin in a subject, comprising applying citronellol. In one aspect of such an embodiment, the inhibition of melanin production and / or whitening the skin is achieved by inhibiting COX2 and / or IL-1α expression in the subject.

[0021] The method according to the present application is for cosmetic purposes and may exclude medical procedures performed by doctors or medical professionals. The method according to the present application may also be a method for supporting cosmetic procedures of a subject.

[0022] The present invention also provides a composition for inhibiting melanin production and / or skin whitening, comprising one or more selected from citronellol, phenethyl alcohol, and nerol, or the agent of the present invention. The composition of the present invention may be a composition for inhibiting melanin production and / or skin whitening. The composition may be a cosmetic, pharmaceutical, or quasi-drug.

[0023] The composition can be applied via any route, such as transdermal, oral, transmucosal, nasal, intravenous, intraarterial, or subcutaneous, but is preferably applied transdermally, i.e., to the skin, from the viewpoint of acting on the skin. The skin can be applied to any part of the body, such as the face, head, neck, limbs, or trunk.

[0024] In the case of cosmetics, the composition can be incorporated into facial or body cosmetics such as lotions, emulsions, serums, creams, lotions, packs, essences, and gels, makeup cosmetics such as foundations, makeup bases, and concealers, and even bath additives. In the case of transdermal pharmaceuticals, the composition can be formulated into topical skin preparations. The form is not particularly limited as long as it is applicable to the skin, and any dosage form can be applied, for example, a solution, emulsion, solid, semi-solid, powder, powder dispersion, water-oil two-layer separation, water-oil-powder three-layer separation, ointment, gel, aerosol, mousse, stick, etc. In addition, bases and excipients commonly used in cosmetics and topical skin preparations, such as preservatives, emulsifiers, and pH adjusters, may be used.

[0025] The amount of active ingredient in the agent or composition of the present invention can be selected as desired from the viewpoint of exerting effects such as melanin production inhibition and skin whitening. For example, one or more selected from citronellol, phenethyl alcohol, and nerol can be blended in a total amount of 0.0005 to 100.0 mM. From the viewpoint of fully exerting the effect, they can be blended preferably at 0.05 mM or more, and more preferably at 0.5 mM or more. On the other hand, since citronellol, phenethyl alcohol, and nerol have an aroma, from the viewpoint of avoiding an overly strong odor, they can be blended preferably at 10.0 mM or less, and more preferably at 5.0 mM or less. The above-mentioned ingredients may be combined in any ratio, and in such cases, it is preferable that the total amount of those ingredients is within the above-mentioned range.

[0026] The present invention further provides citronellol, phenethyl alcohol, and nerol, preferably citronellol, for inhibiting melanin production and / or skin whitening, wherein preferably the inhibition of melanin production and / or skin whitening is mediated by the inhibition of gene expression of COX2 and / or IL-1α.

[0027] In one aspect, the inhibition of melanin production is inhibition of melanin production in the epidermis. In one aspect, the whitening is whitening of the epidermis. The inhibition of melanin production and / or whitening of the epidermis is exerted by suppressing gene expression or protein production of COX2 and / or IL-1α in keratinocytes.

[0028] Furthermore, the present invention also provides the use of one or more selected from citronellol, phenethyl alcohol, and nerol in the manufacture of a medicament for inhibiting melanin production and / or whitening the skin.

[0029] All documents mentioned herein are incorporated by reference in their entirety.

[0030] The following examples of the present invention are for illustrative purposes only and do not limit the technical scope of the present invention. The technical scope of the present invention is limited only by the claims. The present invention may be modified, for example, by adding, deleting, or substituting components of the present invention, provided that the modifications do not depart from the spirit of the present invention.

[0031] To confirm the melanin production inhibitory and / or skin whitening effects of citronellol, phenethyl alcohol, and nerol, the expression of genes involved in these functions was analyzed. More specifically, the expression levels of COX2 and IL-1α were measured by the method described below.

[0032] 1: Cell culture HaCaT cells were cultured in a 24-well plate (Cat No. 3526, Corning, USA) at a density of 10.0 × 10 4The cells were seeded at a density of 10.0% (v / v) fetal bovine serum (FBS, Cat No. SH30071.03, Hyclone, UK) and 1.0% (v / v) antifungal agent (Antibiotic-Antimycotic 100X, Cat No. 15240-062, Invitrogen, USA) in Dulbecco's Modified Eagle Medium (DMEM, Cat No. 043-30085, Wako, Japan) at a density of 10.0% (v / v) cells / well and cultured for 24 hours in a CO2 incubator (CO2 concentration 5%, 37°C). After removing the medium, the cells were replaced with medium supplemented with citronellol (CAS: 106-22-9, Wako Pure Chemical Industries, Ltd. 037-05993), phenethyl alcohol (CAS: 60-12-8, TCI P0084), or nerol (CAS: 106-25-2, TCI N0077) to a final concentration of 0.5 mM, and further cultured for 48 hours in a CO2 incubator. As a control, medium containing no citronellol, phenethyl alcohol, or nerol was used.

[0033] 2: RNA extraction and purification, quantification and purity measurement. RNA was extracted and purified using PureLink™ RNA Mini Kit (Cat No. 12183018A, Invitrogen, USA). A portion of the purified RNA was placed in a UV-transparent 96-well plate and diluted 10-fold with Tris-EDTA Buffer. The absorbance at 230 nm, 260 nm, and 280 nm (OD230, OD260, OD280) was measured using a microplate reader (SPARK (registered trademark) 10M TECAN, Switzerland). The RNA concentration was calculated using OD260, and the RNA concentration was adjusted to 10 μg / mL by dilution with TE Buffer.

[0034] 1-3: Gene Expression Analysis by Real-Time PCR RNA was reverse-transcribed using SuperScript™ IV VILO™ Master Mix with ezDNase (Cat No. 11766050, Invitrogen, USA). 4 μL of SuperScript™ IV VILO™ Master Mix and 6 μL of nuclease-free water were added per well of an 8-tube array. cDNA was synthesized using a real-time PCR system (QuantStudio™ 3, Applied Biosystems, USA) by heating at 25°C for 10 minutes, 50°C for 10 minutes, and 85°C for 5 minutes. Ten microliters of TaqMan® Fast Advanced Master Mix (Cat No. 4444557, Applied Biosystems, USA), 1 μL of TaqMan Gene Expressor, 7 μL of UltraPure™ Distilled Water (Invitrogen, Cat No. 10977-015, USA), and 2 μL of cDNA were added per well to a PCR plate, and the plate was sealed. Real-time qPCR was performed using a COX2 primer (Hs00153133_m1) or an IL-1α (Interleukin 1 Alpha) primer (Hs00174092_m1) and a GAPDH primer (Hs02786624_g1) as an internal standard gene. The threshold cycle (Ct) values ​​for each gene, such as FLG, in cis-3-hexenol-supplemented medium were calculated, and the Ct values ​​were corrected using GAPDH to obtain ΔCt values. Assuming that the gene amount doubles per cycle, the gene expression level in the control was set to 1. The average values ​​from 3 wells of a 24-well plate were used for gene expression analysis.

[0035] The results are shown in Tables 1 to 4 below.

[0036] As shown in Tables 1 to 4, the addition of citronellol, phenethyl alcohol, and nerol reduced the expression of COX2 and IL-1α. These results demonstrate that citronellol, phenethyl alcohol, and nerol have the effect of suppressing the expression of COX2 and IL-1α.

[0037] Based on the above results, it is expected that the inhibition of COX2 and IL-1α gene expression by citronellol, phenethyl alcohol, and nerol will have favorable effects on the skin, such as the inhibition of melanin production and / or whitening.

Claims

1. A melanin production inhibitor containing citronellol or phenethyl alcohol as an active ingredient.

2. An IL-1α gene expression inhibitor containing citronellol or phenethyl alcohol as an active ingredient.

3. A COX2 gene expression inhibitor containing citronellol or phenethyl alcohol as an active ingredient.

4. A cosmetic method for inhibiting melanin production in a subject, comprising applying citronellol or phenethyl alcohol to the subject.

Citation Information

Patent Citations

  • Cyclohexenol derivative and perfume composition

    JP1998077239A

  • Skin care preparation

    JP2003176221A

  • Tyrosinase inhibitors

    US5466718A